Skip to main content
Top
Published in: Current Atherosclerosis Reports 5/2014

Open Access 01-05-2014 | Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox

Author: Harold Bays

Published in: Current Atherosclerosis Reports | Issue 5/2014

Login to get access

Abstract

Among lean populations, cardiovascular disease (CVD) is rare. Among those with increased adiposity, CVD is the commonest cause of worldwide death. The “obesity paradox” describes seemingly contrary relationships between body fat and health/ill-health. Multiple obesity paradoxes exist, and include the anatomic obesity paradox, physiologic obesity paradox, demographic obesity paradox, therapeutic obesity paradox, cardiovascular event/procedure obesity paradox, and obesity treatment paradox. Adiposopathy (“sick fat”) is defined as adipocyte/adipose tissue dysfunction caused by positive caloric balance and sedentary lifestyle in genetically and environmentally susceptible individuals. Adiposopathy contributes to the commonest metabolic disorders encountered in clinical practice (high glucose levels, high blood pressure, dyslipidemia, etc.), all major CVD risk factors. Ockham's razor is a principle of parsimony which postulates that among competing theories, the hypothesis with the fewest assumptions is the one best selected. Ockham’s razor supports adiposopathy as the primary cause of most cases of adiposity-related metabolic diseases, which in turn helps resolve the obesity paradox.
Literature
2.
go back to reference Walker AR. Are health and ill-health lessons from hunter-gatherers currently relevant? Am J Clin Nutr. 2001;73:353–6.PubMed Walker AR. Are health and ill-health lessons from hunter-gatherers currently relevant? Am J Clin Nutr. 2001;73:353–6.PubMed
4.
go back to reference O'Dea K. Cardiovascular disease risk factors in Australian aborigines. Clin Exp Pharmacol Physiol. 1991;18:85–8.PubMedCrossRef O'Dea K. Cardiovascular disease risk factors in Australian aborigines. Clin Exp Pharmacol Physiol. 1991;18:85–8.PubMedCrossRef
5.
go back to reference O'Keefe Jr JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142–6.PubMedCrossRef O'Keefe Jr JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142–6.PubMedCrossRef
6.
10.
go back to reference Haslam D. Letter to the Editor. Re: The science of obesity: what do we really know about what makes us fat? An essay by Gary Taubes. Br Med J. 2013;346:f1050.CrossRef Haslam D. Letter to the Editor. Re: The science of obesity: what do we really know about what makes us fat? An essay by Gary Taubes. Br Med J. 2013;346:f1050.CrossRef
11.
go back to reference Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De sedibus et causis morborum per anatomen indagata’. Int J Obes Relat Metab Disord. 2003;27:534–5.PubMedCrossRef Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni’s ‘De sedibus et causis morborum per anatomen indagata’. Int J Obes Relat Metab Disord. 2003;27:534–5.PubMedCrossRef
12.
go back to reference Ritz E. Metabolic syndrome - what we know and what we don’t know. J Am Soc Nephrol. 2007;18:1619–23.CrossRef Ritz E. Metabolic syndrome - what we know and what we don’t know. J Am Soc Nephrol. 2007;18:1619–23.CrossRef
13.
go back to reference Vague J. La differenciation sexuelle, facteur determinant des formes de l’obesite. Presse Med. 1947;55:339.PubMed Vague J. La differenciation sexuelle, facteur determinant des formes de l’obesite. Presse Med. 1947;55:339.PubMed
14.••
go back to reference Bays HE. Adiposopathy is “sick fat” a cardiovascular disease? J Am Coll Cardiol. 2011;57:2461–73. This is an in-depth review of adiposopathy and CVD.PubMedCrossRef Bays HE. Adiposopathy is “sick fat” a cardiovascular disease? J Am Coll Cardiol. 2011;57:2461–73. This is an in-depth review of adiposopathy and CVD.PubMedCrossRef
15.
go back to reference Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Futur Cardiol. 2005;1:39–59.CrossRef Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Futur Cardiol. 2005;1:39–59.CrossRef
17.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21:1–6.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol. 2006;21:1–6.PubMedCrossRef
18.
go back to reference Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–8.PubMedCrossRef
20.
go back to reference Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343–68.PubMedCrossRef Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6:343–68.PubMedCrossRef
21.
go back to reference Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–304.PubMedCrossRef Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–304.PubMedCrossRef
22.
go back to reference Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes. 1995;44:369–74.PubMedCrossRef Stern MP. Diabetes and cardiovascular disease. The “common soil” hypothesis. Diabetes. 1995;44:369–74.PubMedCrossRef
23.
go back to reference Pladevall M, Singal B, Williams LK, Brotons C, Guyer H, Sadurni J, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006;29:113–22.PubMedCrossRef Pladevall M, Singal B, Williams LK, Brotons C, Guyer H, Sadurni J, et al. A single factor underlies the metabolic syndrome: a confirmatory factor analysis. Diabetes Care. 2006;29:113–22.PubMedCrossRef
24.
25.
go back to reference Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–211.PubMedCrossRef Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res. 2004;12:1197–211.PubMedCrossRef
26.
go back to reference Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, et al. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract. 2008;62:1474–83.PubMedCentralPubMedCrossRef Bays HE, Gonzalez-Campoy JM, Henry RR, Bergman DA, Kitabchi AE, Schorr AB, et al. Is adiposopathy (sick fat) an endocrine disease? Int J Clin Pract. 2008;62:1474–83.PubMedCentralPubMedCrossRef
27.•
go back to reference Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:304–83. This is an in-depth review of adiposopathy and dyslipidemia.PubMedCrossRef Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7:304–83. This is an in-depth review of adiposopathy and dyslipidemia.PubMedCrossRef
28.••
go back to reference Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol. 2012;110:4B–12B. This is an in-depth review of adiposopathy and diabetes mellitus.PubMedCrossRef Bays HE. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating “sick fat” through improving fat function with antidiabetes therapies. Am J Cardiol. 2012;110:4B–12B. This is an in-depth review of adiposopathy and diabetes mellitus.PubMedCrossRef
29.
go back to reference Yang J, Kang J, Guan Y. The mechanisms linking adiposopathy to type 2 diabetes. Front Med. 2013;7:433–44.PubMedCrossRef Yang J, Kang J, Guan Y. The mechanisms linking adiposopathy to type 2 diabetes. Front Med. 2013;7:433–44.PubMedCrossRef
30.
go back to reference Appachi S, Kashyap SR. ‘Adiposopathy’ and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol. 2013;28:540–6.PubMed Appachi S, Kashyap SR. ‘Adiposopathy’ and cardiovascular disease: the benefits of bariatric surgery. Curr Opin Cardiol. 2013;28:540–6.PubMed
31.
go back to reference Bays HE, Laferrere B, Dixon J, Aronne L, Gonzalez-Campoy JM, Apovian C, et al. Adiposopathy and bariatric surgery: is ‘sick fat’ a surgical disease? Int J Clin Pract. 2009;63:1285–300.PubMedCentralPubMedCrossRef Bays HE, Laferrere B, Dixon J, Aronne L, Gonzalez-Campoy JM, Apovian C, et al. Adiposopathy and bariatric surgery: is ‘sick fat’ a surgical disease? Int J Clin Pract. 2009;63:1285–300.PubMedCentralPubMedCrossRef
32.
go back to reference Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62:1513–21.PubMedCrossRef Van de Voorde J, Pauwels B, Boydens C, Decaluwe K. Adipocytokines in relation to cardiovascular disease. Metabolism. 2013;62:1513–21.PubMedCrossRef
33.
go back to reference Seaman DR. Body mass index and musculoskeletal pain: is there a connection? Chiropr Man Ther. 2013;21:15.CrossRef Seaman DR. Body mass index and musculoskeletal pain: is there a connection? Chiropr Man Ther. 2013;21:15.CrossRef
34.
go back to reference Mauro CR, Nguyen BT, Yu P, Tao M, Gao I, Seidman MA, et al. Inflammatory “adiposopathy” in major amputation patients. Ann Vasc Surg. 2013;27:346–52.PubMedCrossRefPubMedCentral Mauro CR, Nguyen BT, Yu P, Tao M, Gao I, Seidman MA, et al. Inflammatory “adiposopathy” in major amputation patients. Ann Vasc Surg. 2013;27:346–52.PubMedCrossRefPubMedCentral
35.
go back to reference Mauro CR, Ilonzo G, Nguyen BT, Yu P, Tao M, Gao I, et al. Attenuated adiposopathy in perivascular adipose tissue compared with subcutaneous human adipose tissue. Am J Surg. 2013;206:241–4.PubMedCrossRef Mauro CR, Ilonzo G, Nguyen BT, Yu P, Tao M, Gao I, et al. Attenuated adiposopathy in perivascular adipose tissue compared with subcutaneous human adipose tissue. Am J Surg. 2013;206:241–4.PubMedCrossRef
36.
go back to reference Pepping JK, Freeman LR, Gupta S, Keller JN, Bruce-Keller AJ. NOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet. Am J Physiol Endocrinol Metab. 2013;304:E392–404.PubMedCentralPubMedCrossRef Pepping JK, Freeman LR, Gupta S, Keller JN, Bruce-Keller AJ. NOX2 deficiency attenuates markers of adiposopathy and brain injury induced by high-fat diet. Am J Physiol Endocrinol Metab. 2013;304:E392–404.PubMedCentralPubMedCrossRef
37.
go back to reference Duntas L, Micic D. Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk. Expert Rev Cardiovasc Ther. 2012;10:797–803.PubMedCrossRef Duntas L, Micic D. Adiposopathy and thyroid disease: tracing the pathway to cardiovascular risk. Expert Rev Cardiovasc Ther. 2012;10:797–803.PubMedCrossRef
38.
go back to reference Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease. Expert Rev Cardiovasc Ther. 2009;7:1429–45.PubMedCrossRef Bays HE. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for ‘sick fat’ and metabolic disease. Expert Rev Cardiovasc Ther. 2009;7:1429–45.PubMedCrossRef
39.
go back to reference Medina-Gomez G, Vidal-Puig A. Tejido adiposo como diana terapéutica en la obesidad. Endocrinol Nutr. 2009;56:404–11.PubMedCrossRef Medina-Gomez G, Vidal-Puig A. Tejido adiposo como diana terapéutica en la obesidad. Endocrinol Nutr. 2009;56:404–11.PubMedCrossRef
40.
go back to reference Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013;19(3):1–82.PubMedCrossRef Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013;19(3):1–82.PubMedCrossRef
42.
go back to reference Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the theory of everything. Expert Rev Cardiovasc Ther. 2005;3:393–404.PubMedCrossRef Bays H. Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the theory of everything. Expert Rev Cardiovasc Ther. 2005;3:393–404.PubMedCrossRef
43.
go back to reference Hur SJ, Kim DH, Chun SC, Lee SK. Effect of adenovirus and influenza virus infection on obesity. Life Sci. 2013;93:531–5.PubMedCrossRef Hur SJ, Kim DH, Chun SC, Lee SK. Effect of adenovirus and influenza virus infection on obesity. Life Sci. 2013;93:531–5.PubMedCrossRef
44.
go back to reference Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39–58.PubMedCrossRef Shen J, Obin MS, Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med. 2013;34:39–58.PubMedCrossRef
45.
go back to reference Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309:2250–61.PubMedCrossRef Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309:2250–61.PubMedCrossRef
46.
go back to reference Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring). 2010;18:1510–5.CrossRef Magkos F, Fabbrini E, Mohammed BS, Patterson BW, Klein S. Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring). 2010;18:1510–5.CrossRef
47.
go back to reference Perreault L, Bergman BC, Hunerdosse DM, Playdon MC, Eckel RH. Inflexibility in intramuscular triglyceride fractional synthesis distinguishes prediabetes from obesity in humans. Obesity (Silver Spring). 2010;18:1524–31.CrossRef Perreault L, Bergman BC, Hunerdosse DM, Playdon MC, Eckel RH. Inflexibility in intramuscular triglyceride fractional synthesis distinguishes prediabetes from obesity in humans. Obesity (Silver Spring). 2010;18:1524–31.CrossRef
48.
go back to reference McCarty DE. Beyond Ockham’s razor: redefining problem-solving in clinical sleep medicine using a “five-finger” approach. J Clin Sleep Med. 2010;6:292–6.PubMedCentralPubMed McCarty DE. Beyond Ockham’s razor: redefining problem-solving in clinical sleep medicine using a “five-finger” approach. J Clin Sleep Med. 2010;6:292–6.PubMedCentralPubMed
49.
go back to reference Bays HE, Fox KM, Grandy S. Anthropometric measurements and diabetes mellitus: clues to the “pathogenic” and “protective” potential of adipose tissue. Metab Syndr Relat Disord. 2010;8:307–15.PubMedCrossRef Bays HE, Fox KM, Grandy S. Anthropometric measurements and diabetes mellitus: clues to the “pathogenic” and “protective” potential of adipose tissue. Metab Syndr Relat Disord. 2010;8:307–15.PubMedCrossRef
50.
go back to reference Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004;28 Suppl 4:S12–21.PubMedCrossRef Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord. 2004;28 Suppl 4:S12–21.PubMedCrossRef
51.
go back to reference Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.PubMedCentralPubMedCrossRef Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5:1544–60.PubMedCentralPubMedCrossRef
53.
go back to reference Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol. 2013;169:166–76.PubMedCrossRef Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int J Cardiol. 2013;169:166–76.PubMedCrossRef
54.
go back to reference Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.PubMedCentralPubMedCrossRef Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006;5:1.PubMedCentralPubMedCrossRef
55.
go back to reference Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–6.PubMedCrossRef Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–6.PubMedCrossRef
56.••
go back to reference Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the Obesity Society and the American Society of Hypertension. Obesity (Silver Spring). 2013;21:8–24. This is an in-depth review of obesity and hypertension.CrossRef Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment—a position paper of the Obesity Society and the American Society of Hypertension. Obesity (Silver Spring). 2013;21:8–24. This is an in-depth review of obesity and hypertension.CrossRef
57.
go back to reference Chen K, Xie Y, Hu P, Zhao S, Mo Z. Multiple symmetric lipomatosis: substantial subcutaneous adipose tissue accumulation did not induce glucose and lipid metabolism dysfunction. Ann Nutr Metab. 2010;57:68–73.PubMedCrossRef Chen K, Xie Y, Hu P, Zhao S, Mo Z. Multiple symmetric lipomatosis: substantial subcutaneous adipose tissue accumulation did not induce glucose and lipid metabolism dysfunction. Ann Nutr Metab. 2010;57:68–73.PubMedCrossRef
58.
go back to reference Vigouroux C, Caron-Debarle M, Le Dour C, Magre J, Capeau J. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int J Biochem Cell Biol. 2011;43:862–76.PubMedCrossRef Vigouroux C, Caron-Debarle M, Le Dour C, Magre J, Capeau J. Molecular mechanisms of human lipodystrophies: from adipocyte lipid droplet to oxidative stress and lipotoxicity. Int J Biochem Cell Biol. 2011;43:862–76.PubMedCrossRef
59.
go back to reference Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol. 2009;20:300–8.PubMedCrossRef Simha V, Garg A. Inherited lipodystrophies and hypertriglyceridemia. Curr Opin Lipidol. 2009;20:300–8.PubMedCrossRef
60.
go back to reference Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: the “metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health. 2014;14:14.PubMedCentralPubMedCrossRef Roberson LL, Aneni EC, Maziak W, Agatston A, Feldman T, Rouseff M, et al. Beyond BMI: the “metabolically healthy obese” phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health. 2014;14:14.PubMedCentralPubMedCrossRef
61.•
go back to reference Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013;159:758–69. Not all patients who are “metabolically healthy but obese” are truly healthy.PubMedCrossRef Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013;159:758–69. Not all patients who are “metabolically healthy but obese” are truly healthy.PubMedCrossRef
62.
go back to reference Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud’homme D, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90:4145–50.PubMedCrossRef
63.
go back to reference Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56:426–33.PubMedCrossRef Oliveros E, Somers VK, Sochor O, Goel K, Lopez-Jimenez F. The concept of normal weight obesity. Prog Cardiovasc Dis. 2014;56:426–33.PubMedCrossRef
64.
go back to reference McCarty MF. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med Hypotheses. 2003;61:173–6.PubMedCrossRef McCarty MF. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med Hypotheses. 2003;61:173–6.PubMedCrossRef
65.
66.
go back to reference Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singap. 2009;38:66–9.PubMed Low S, Chin MC, Ma S, Heng D, Deurenberg-Yap M. Rationale for redefining obesity in Asians. Ann Acad Med Singap. 2009;38:66–9.PubMed
67.
go back to reference Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271–8.PubMedCentralPubMedCrossRef Gavrilova O, Marcus-Samuels B, Graham D, Kim JK, Shulman GI, Castle AL, et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest. 2000;105:271–8.PubMedCentralPubMedCrossRef
68.
go back to reference Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463–78.PubMedCrossRef Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89:463–78.PubMedCrossRef
69.
go back to reference de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013;8:e63623.PubMedCentralPubMedCrossRef de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013;8:e63623.PubMedCentralPubMedCrossRef
70.
go back to reference Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–57.PubMedCrossRef Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004;350:2549–57.PubMedCrossRef
71.
go back to reference Blum A, Simsolo C, Sirchan R, Haiek S. “Obesity paradox” in chronic obstructive pulmonary disease. Isr Med Assoc J. 2011;13:672–5.PubMed Blum A, Simsolo C, Sirchan R, Haiek S. “Obesity paradox” in chronic obstructive pulmonary disease. Isr Med Assoc J. 2011;13:672–5.PubMed
72.
go back to reference Benderly M, Boyko V, Goldbourt U. Relation of body mass index to mortality among men with coronary heart disease. Am J Cardiol. 2010;106:297–304.PubMedCrossRef Benderly M, Boyko V, Goldbourt U. Relation of body mass index to mortality among men with coronary heart disease. Am J Cardiol. 2010;106:297–304.PubMedCrossRef
73.
go back to reference McAuley PA, Kokkinos PF, Oliveira RB, Emerson BT, Myers JN. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc. 2010;85:115–21.PubMedCentralPubMedCrossRef McAuley PA, Kokkinos PF, Oliveira RB, Emerson BT, Myers JN. Obesity paradox and cardiorespiratory fitness in 12,417 male veterans aged 40 to 70 years. Mayo Clin Proc. 2010;85:115–21.PubMedCentralPubMedCrossRef
74.
go back to reference Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251–8.PubMedCrossRef Lavie CJ, Cahalin LP, Chase P, Myers J, Bensimhon D, Peberdy MA, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251–8.PubMedCrossRef
75.
go back to reference Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M, et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail. 2011;13:200–6.PubMedCentralPubMedCrossRef Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M, et al. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail. 2011;13:200–6.PubMedCentralPubMedCrossRef
76.
go back to reference Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370:233–44.PubMedCrossRef Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370:233–44.PubMedCrossRef
77.
go back to reference Bellows CF, Zhang Y, Simmons PJ, Khalsa AS, Kolonin MG. Influence of BMI on level of circulating progenitor cells. Obesity (Silver Spring). 2011;19:1722–6.CrossRef Bellows CF, Zhang Y, Simmons PJ, Khalsa AS, Kolonin MG. Influence of BMI on level of circulating progenitor cells. Obesity (Silver Spring). 2011;19:1722–6.CrossRef
78.
go back to reference Kollar K, Cook MM, Atkinson K, Brooke G. Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol. 2009;2009:904682.PubMedCentralPubMedCrossRef Kollar K, Cook MM, Atkinson K, Brooke G. Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol. 2009;2009:904682.PubMedCentralPubMedCrossRef
79.
go back to reference Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sorensen M, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2006;92:768–74.PubMedCentralPubMedCrossRef Wang Y, Johnsen HE, Mortensen S, Bindslev L, Ripa RS, Haack-Sorensen M, et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart. 2006;92:768–74.PubMedCentralPubMedCrossRef
80.
go back to reference Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5–13.CrossRef Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring). 2014;22:5–13.CrossRef
81.
go back to reference Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.PubMedCrossRef Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.PubMedCrossRef
82.
go back to reference Moustarah F, Gilbert A, Despres JP, Tchernof A. Impact of gastrointestinal surgery on cardiometabolic risk. Curr Atheroscler Rep. 2012;14:588–96.PubMedCrossRef Moustarah F, Gilbert A, Despres JP, Tchernof A. Impact of gastrointestinal surgery on cardiometabolic risk. Curr Atheroscler Rep. 2012;14:588–96.PubMedCrossRef
83.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
84.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1161/01.cir.0000437738.63853.7a Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.​1161/​01.​cir.​0000437738.​63853.​7a
Metadata
Title
Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox
Author
Harold Bays
Publication date
01-05-2014
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 5/2014
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-014-0409-1

Other articles of this Issue 5/2014

Current Atherosclerosis Reports 5/2014 Go to the issue

Vascular Biology(RS Rosenson, Section Editor)

The Endothelium in Diabetic Nephropathy

Vascular Biology (RS Rosenson, Section Editor)

Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors

Genetics (AJ Marian, Section Editor)

Pharmacogenetics of Antiplatelet Therapy

Genetics (AJ Marian, Section Editor)

Noncoding RNAs and Atherosclerosis

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.